Impact of the COVID-19 pandemic on healthcare workers risk of infection and outcomes in a large, integrated health system.

Anita D Misra-Hebert (misraa@ccf.org)
Cleveland Clinic

Lara Jehi
Cleveland Clinic

Xinge Ji
Cleveland Clinic

Amy S. Nowacki
Cleveland Clinic

Steven Gordon
Cleveland Clinic

Paul Terpeluk
Cleveland Clinic

Mina K. Chung
Cleveland Clinic

Reena Mehra
Cleveland Clinic

Katherine M. Dell
Cleveland Clinic Children's Hospital

Nathan Pennell
Cleveland Clinic

Aaron Hamilton
Cleveland Clinic

Alex Milinovich
Cleveland Clinic

Michael W. Kattan
Cleveland Clinic

James B. Young
Cleveland Clinic

Research Article
Abstract

**Background:** Understanding the impact of the COVID-19 pandemic on healthcare workers (HCW) is crucial.

**Objective:** Utilizing a health system COVID-19 research registry, we assessed HCW risk for COVID-19 infection, hospitalization and intensive care unit (ICU) admission.

**Design:** Retrospective cohort study with overlap propensity score weighting.

**Participants:** Individuals tested for SARS-CoV-2 infection in a large academic healthcare system (N=72,909) from March 8-June 9 2020 stratified by HCW and patient-facing status.

**Main Measures:** SARS-CoV-2 test result, hospitalization, and ICU admission for COVID-19 infection.

**Key Results:** Of 72,909 individuals tested, 9.0% (551) of 6,145 HCW tested positive for SARS-CoV-2 compared to 6.5% (4,353) of 66,764 non-HCW. The HCW were younger than non-HCW (median age 39.7 vs. 57.5, p<0.001) with more females (proportion of males 21.5 vs. 44.9%, p<0.001), higher reporting of COVID-19 exposure (72 vs. 17 %, p<0.001) and fewer comorbidities. However, the overlap propensity score weighted proportions were 8.9 vs. 7.7 for HCW vs. non-HCW having a positive test with weighted odds ratio (OR) 1.17, 95% confidence interval (CI) 0.99-1.38. Among those testing positive, weighted proportions for hospitalization were 7.4 vs. 15.9 for HCW vs. non-HCW with OR of 0.42 (CI 0.26-0.66) and for ICU admission: 2.2 vs. 4.5 for HCW vs. non-HCW with OR of 0.48 (CI 0.20 -1.04). Those HCW identified as patient-facing compared to not had increased odds of a positive SARS-CoV-2 test (OR 1.60, CI 1.08-2.39, proportions 8.6 vs. 5.5), but no statistically significant increase in hospitalization (OR 0.88, CI 0.20-3.66, proportions 10.2 vs. 11.4) and ICU admission (OR 0.34, CI 0.01-3.97, proportions 1.8 vs. 5.2).

**Conclusions:** In a large healthcare system, HCW had similar odds for testing SARS-CoV-2 positive, but lower odds of hospitalization compared to non-HCW. Patient-facing HCW had higher odds of a positive test. These results are key to understanding HCW risk mitigation during the COVID-19 pandemic.

Introduction

Understanding the risks associated with the COVID-19 pandemic on healthcare workers (HCW), including the risk of acquisition at work vs other settings, is crucial. Prediction of risk can inform how to protect HCWs such as recommendations on use of personal protective equipment (PPE) at work or in the community. The presence of specific symptoms in HCW (China, US) and symptoms predicting SARS-CoV-2 test positivity in HCW (Netherlands) have been reported as well as characteristics associated with HCW deaths (China). Based upon data from the 2018 National Health Interview Survey, it was estimated that 26.6% of patient facing HCW were at increased risk for poor outcomes from COVID-19 infection.
because of their comorbidities or age. Reported experiences in China, Italy and Solano County, CA without initial use of PPE showed higher percentages of HCW testing positive for COVID-19. In contrast, a screening study of HCW in England showed no significant difference in positive results between clinical and nonclinical staff with implementation of isolation and PPE protocols perhaps suggesting predominant community rather than nosocomial transmission patterns. The extent of risk modification with PPE remains unclear. A recent prospective study in the United Kingdom and US suggested a five-fold increased risk for HCW caring for patients with COVID-19 compared to HCW not caring for patients with COVID-19, even with the use of PPE while another study of HCW in a large healthcare system showed a decrease in positive tests for SARS-CoV-2 associated with a universal masking recommendation. This heterogeneous landscape makes it difficult for the HCW community to determine actual risk of acquiring COVID-19 in healthcare vs. community settings and the effectiveness of various risk-mitigating strategies.

The Cleveland Clinic Health System (CCHS) is a large, integrated health system with 55,574 eligible employees in Ohio & Florida. The CCHS initiated multiple COVID-19 related public health initiatives to mitigate the spread of the disease and its impact on the HCW community. In parallel, we maintained a rigorous, comprehensive, and prospective registry capturing disease risk and progression in all individuals tested for COVID-19 in our health system. In this study, we aimed to assess whether HCW are at higher risk for COVID-19 infection, COVID-19 related hospitalization, and intensive care unit (ICU) admission compared to non-HCW using advanced statistical methodology to account for various confounders.

**Methods**

**Cohort definition**

*COVID-19 Cleveland clinic enterprise registry:* All patients, regardless of age, who were tested for COVID-19 at all CCHS locations in Ohio and Florida were included in this research registry. For this study, all individuals who were tested for COVID-19 in the CCHS between March 8, 2020 and June 9, 2020 were studied. This registry provides better representation of the overall population than testing restricted to one geographic health system site. Registry variables were chosen to reflect available literature on COVID-19 disease characterization, progression, and proposed treatments, including medications initially thought to have potential for benefit after drug-repurposing network analysis. Capture of detailed research data was facilitated by the creation of standardized clinical templates implemented across the healthcare system as patients were seeking care for COVID-19-related concerns. Data were extracted via previously validated automated feeds from electronic health records (EPIC; EPIC Systems Corporation) and manually by a study team trained on uniform sources for the study variables. Study data were collected and managed using REDCap electronic data capture tools hosted at the Cleveland Clinic. The COVID-19 Research Registry team includes a “Reviewer” group and a “Quality Assurance” group. The reviewers were responsible for manually abstracting and entering a subset of variables that cannot be automatically extracted from the electronic health record (EHR). Reviewers were also asked to verify
high-priority variables that have been automatically pulled into the database from EPIC. The Cleveland Clinic Institutional Review Board approved this study and waived the requirements for written informed consent.

**Identification of HCW:** Individuals were identified as HCW through CCHS Occupational Health and their job description was identified as having direct contact with patients or “patient-facing” vs. non-patient facing based upon the listing in the CCHS Human Resources database.

**Public health and employer-initiated risk mitigation measures**

Public health guidelines for CCHS employees and availability of testing for COVID-19 changed rapidly between 3/6/2020-4/24/2020 (Appendix 1), the most relevant being the recommendation for universal masking for CCHS employees on 4/7/2020 and requirement on 4/24/2020. Regarding state public health orders, a stay at home order was issued in Ohio on 3/22/2020 with phased re-opening in May starting with restaurants and bars on 5/14/202018 and in Florida a public health advisory was issued on 3/25/2020 addressing vulnerable populations, private gatherings, and workforce density19 with reopening beginning on 5/18/2020.20

**Statistical Analysis**

All descriptive statistics were reported as counts (percentages) or median (interquartile ranges [IQRs]). For comparison of demographic variables and comorbidities among cohorts, Wilcoxon signed-rank tests were used for numeric variables, while χ² or Fisher exact tests were used for categorical variables. To address differences in baseline characteristics of non-HCW and HCW, specifically as related to underlying comorbidities, and the limitations of current literature that failed to account for such differences, we leveraged appropriate statistical methodology to study our research questions. Overlap propensity score21,22 weighting was performed to address potential confounding in comparing HCW to non-HCW given their baseline differences. The overlap propensity score weighting method was chosen given its benefits of preservation of numbers of individuals in each group and of achieving higher levels of precision in the resulting estimates. This methodology is preferred when the propensity score distributions among the groups are dissimilar and when the propensity scores are clustered near the extremes (i.e. close to zero or one). A propensity score for being a HCW was estimated from a multivariable logistic regression model. For the outcome of being test positive for COVID-19, the propensity score logistic regression model included covariates that were found to be associated with a positive COVID-19 test outcome in our previous work.23 For the outcomes of hospital and intensive care unit (ICU) admission of COVID-19 test positive patients, the propensity score covariates are those that were found associated with COVID-19 hospitalization outcome in our previous work including age, race, ethnicity, gender, smoking history, body mass index, median income, population per housing unit, presenting symptoms (including fever, fatigue, shortness of breath, diarrhea, vomiting), comorbidities (including asthma, hypertension, diabetes, immunosuppressive disease), medications (including immunosuppressive treatment, non-steroidal anti-inflammatory drugs [NSAIDs]), and laboratory values
(including pre-testing platelets, aspartate aminotransferase, blood urea nitrogen, chloride, and potassium).

The overlap propensity score weighting method was then applied where each patient’s statistical weight is the probability of that patient being assigned to the opposite group.\textsuperscript{21} Overlap propensity score weighted logistic regression models were used to investigate associations between HCW status and the probability of testing positive for SARS-CoV-2, hospital admission for COVID-19 and ICU admission for COVID-19 illness. The results are thus reported as weighted proportions, odds ratios and 95% confidence intervals. All statistical analyses were performed using R 3.5 and SAS version 9.4 (SAS Institute). \textit{P} values were 2-sided, with a significance threshold of .05.

We then used locally weighted regression smoother (LOESS) to summarize the trend of COVID-19 test positivity through the study period for HCW and non-HCW as related to the public health measures instituted at the state level in Ohio and those specific to the CCHS.

\section*{Results}

\textbf{Overall tested cohort characteristics:} Of the 72,909 individuals tested for COVID-19 in the CCHS Research Registry, there were 6,145 HCW and 66,764 non-HCW with over 90\% of HCW and 75\% of non-HCW tested from Ohio. There were 9\% of HCW who tested positive for COVID-19 compared to 6.5\% of non-HCW, \textit{p}<0.001 (Table 1). The HCW tested were younger than non-HCW (median age 39.7 vs. 57.5, \textit{p}<0.001) with more females (proportion of males 21.5 vs. 44.9\%, \textit{p}<0.001), higher proportion of Asian and lower proportion of Black persons (3.4 vs. 1.0\% and 16.2 vs. 18.3\%, respectively, \textit{p}<0.001), higher proportion identifying as non-Hispanic (90.8 vs. 87.6\%, \textit{p}<0.001), higher median income, and higher proportion of non-smokers. The neighborhood characteristics of population density as measured per square kilometer was similar for tested HCW vs. non-HCW while the population per housing unit was slightly higher. The HCW were more likely to report an exposure to COVID-19 (72.0\% vs. 17.0\%, \textit{p}<0.001) and also to report having a family member with COVID-19 (28.3 vs. 14.2\%, \textit{p} 0.005). Regarding presenting symptoms, a slightly higher proportion of HCW reported cough (32.0 vs. 29.6\%, \textit{p} 0.001), a lower proportion reported fever (15.0 vs. 19.5\%, \textit{p}<0.001) or shortness of breath (14.6 vs. 25.7\%, \textit{p}<0.001), while a higher proportion reported diarrhea (11.9 vs. 9.5\%, \textit{p}<0.001) and lower proportion reported vomiting (7.4 vs. 9.7\%, \textit{p}<0.001). Of note, the tested HCW were, in general, healthier than the non-HCW group. The HCW had a lower proportion of several comorbidities including chronic obstructive pulmonary disease (COPD)/emphysema, diabetes, hypertension, coronary artery disease, heart failure, cancer, history of transplant, or immunosuppressive disease and were more likely to have received the influenza vaccine (85.9 vs. 45.4\%, \textit{p}<0.001). The HCW tested had a lower proportion of previous prescriptions for immunosuppressive treatment, NSAIDs, steroids, carvedilol, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or melatonin.

\textbf{COVID-19 cohort characteristics and outcomes:} There were 551 HCW and 4,353 non-HCW who tested positive for COVID-19 (Appendix Table 2). Of those who tested positive for COVID-19, a lower proportion
of HCW were hospitalized compared to non-HCW (38 or 6.9% HCW vs. 1205 or 27.7% non-HCW) or were admitted to the intensive care unit (10 or 1.8% HCW vs. 470 or 10.8% non-HCW). In the group who tested positive for COVID-19, there was a greater proportion of HCW of Asian and White race compared to non-HCW (2.9 vs. 0.8% and 61.0 vs 56.4%, respectively), a similar proportion of HCW with a positive COVID-19 test had presenting symptoms of cough, fatigue, diarrhea, loss of appetite, and vomiting and a lower proportion had fever or shortness of breath. Lower proportions of HCW testing positive had COPD/emphysema, diabetes, coronary artery disease, heart failure, cancer, or immunosuppressive disease and were previously prescribed carvedilol, angiotensin converting enzyme inhibitors, angiotensin receptor blockers or melatonin compared to non-HCW. The neighborhood population characteristics of population density or population per housing unit did not differ for those HCW who tested positive and median income was slightly higher compared to non-HCW.

**Overlap propensity weighting.** Using the variables in the prediction model for COVID-19 test positivity, overlap propensity score weighting (Table 2) resulted in propensity score weighted proportions of 7.7 vs. 8.9 for non-HCW vs. HCW having a positive test and produced an overlap propensity score weighted odds ratio of 1.17 with a 95% confidence interval (CI) of 0.99-1.38 for a HCW having a positive test compared to a non-HCW (Figure 1a). Then using the variables which predicted hospitalization for COVID-19 infection, overlap propensity score weighting was applied (Table 3) with weighted proportions for being hospitalized 15.9 vs. 7.4 for non-HCW vs. HCW, an odds ratio of 0.42 (CI 0.26 -0.66) for a HCW being hospitalized for COVID-19 compared to a non-HCW. For ICU admission, weighted proportions were 4.5 vs. 2.2 for non-HCW vs. HCW with an odds ratio of 0.48 (CI 0.20-1.04) for HCW being admitted to the ICU compared to non-HCW (Figure 1a).

**Subgroup analysis**

We then compared characteristics of HCW identified as having positions that required direct contact with patients (“patient facing”) and those that did not. There were 5,159 HCW with patient-facing positions and 986 HCW in non-patient facing roles (Appendix Table 3). The HCW with patient-facing roles were younger (median age 38 vs. 47 years, p<0.001), with more females (proportion males 20.6 vs. 26.2%, p < 0.001), lower proportion of Black race and higher Asian race, and with greater proportion reporting exposure to COVID-19 (73.7 vs. 62.9%, p < 0.001). The patient-facing HCW had lower proportions presenting with fatigue or shortness of breath and higher proportion with loss of appetite. There were no significant differences in laboratory values upon presentation. The patient-facing HCW had lower proportions of some previously prescribed medications including NSAIDs, steroids, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and melatonin. The patient-facing HCW group had lower proportions of comorbidities including COPD/emphysema, diabetes, hypertension, coronary artery disease, cancer, connective tissue disease, and immunosuppressive disease. Applying the overlap propensity score weighting (Appendix Tables 4, 5; Figure 1b) showed patient-facing HCW with increased odds of having a positive SARS-CoV-2 test result (OR 1.60, CI 1.08-2.39, weighted proportions 8.6 vs. 5.5), and lower but non-significant odds of hospital admission (OR 0.88, CI 0.20-3.66, proportions 10.2 vs. 11.4) and ICU admission (OR 0.34, CI 0.01-3.97, proportions 1.8 vs. 5.2).
Temporal relationship between disease prevention measures and positive tests

The summary of the trend of SARS-CoV-2 positive test results in the study period is shown in Figure 2. The overall proportion of positive COVID-19 test results decreased during the study period and the trend for HCW and followed that of non-HCW.

Discussion

Our analysis of HCW compared to non-HCW who were tested for SARS-CoV-2 in one health system with 2 geographic locations (Ohio, Florida), and which controlled for significant differences in baseline characteristics between the HCW and non-HCW groups, showed that the odds of having a positive COVID-19 test were not significantly different for HCW compared to non-HCW, and HCW had lower odds of subsequent hospitalization, and without statistically significant differences in ICU admission compared to non-HCW once they tested positive. The HCW classified as having patient-facing positions had higher and significant odds of a positive COVID-19 test with insignificant differences detected compared to non-patient facing HCW in outcomes of hospitalization or ICU admission. We found a similar proportion of HCW with a positive COVID-19 test had presenting symptoms of cough, fatigue, diarrhea, loss of appetite, and vomiting while a lower proportion had fever or shortness of breath. We note that we were not able to capture the symptoms of loss of taste and/or smell and that these symptoms may be common especially with mild cases of COVID-19.24,25

The overall proportion of COVID-19 positive tests in HCW was low and decreased during the study period corresponding with implementation of risk-mitigation measures in our health system such as the recommendations for universal masking and physical distancing but also followed the trend for non-HCW. Several of the previous studies of HCW risk for infection during the COVID-19 pandemic were limited by their sample sizes,7–9 lack of generalizability for healthcare systems that have adequate access to PPE,7–9 methodology relying on self-report,12 limited ability to adjust for known risk factors of disease susceptibility and progression7–10,12 and lacking data to investigate the relative effects of dual exposure of HCW to COVID-19 in the community versus the workplace.7–10,12 The fact that HCW identified as patient-facing had a significantly higher odds for SARS-CoV-2 test positivity suggests an increased risk of COVID-19 infection with work exposure. However, it is important to note in our study that that over 70% of the HCW group reported an exposure to COVID-19 with 28% reporting exposure to a family member with COVID-19. In our study, we were not able to confirm if the patient-facing HCW were working in patient-facing areas the 14-day period before the test was ordered when exposure could have occurred, or whether the exposure occurred with or without PPE - both in the workplace or in the community, or the relative contribution of initially prioritizing testing availability to HCW with reported exposures. While the risk to HCW attributed to community spread may not be captured in our available data, the reported exposure risk including the higher proportion of HCW vs. non-HCW reporting exposure to a family member with COVID-19 suggests a degree of community acquisition of infection. A potential contributing factor to community acquisition is that HCWs, particularly patient-facing HCW, are less able
to follow stay-at-home guidelines or work remotely from home. Indeed, while PPE use is associated with decrease risk of infection from coronavirus, a recent report estimated less than 5% risk to HCW inadvertently exposed to patients not known to be SARS-CoV-2-positive at the time of initial exposure with exposure likely occurring without appropriate PPE suggesting that the work exposure risk may actually be low. However, universal pandemic precautions have been recommended for optimal risk mitigation for HCW.

**Conclusion**

In our analysis of one healthcare system which implemented significant risk mitigation strategies to prevent the spread of COVID-19 infection, and which controlled for significant baseline differences in HCW compared to non-HCW, the odds for SARS-CoV-2 infection were similar for HCW and non-HCW and HCW had lower odds for COVID-19 related hospitalization. The patient facing HCW had higher odds of SARS-CoV-2 infection.

**Declarations**

**Acknowledgements**

The authors report no conflict of interest related to this work.

Dr. Misra-Hebert receives funding from the Agency for Healthcare Research and Quality grant # K08HS024128 and reports grants from NHLBI, grants from Novo Nordisk, Inc, grants from Merck Inc., grants from Boehringer Ingelheim Pharmaceuticals, Inc, outside the submitted work. Dr. Jehi receives funding from the National Institute of Neurological Disorders and Stroke R01 NS097719, and from the National Center for Advancing Translational Science UL1TR002548 outside the submitted work. Dr. Pennell receives consulting fees from Merck, BMS, Eli Lilly, Genentech, AstraZeneca, G1 Therapeutics and Amgen outside the submitted work. Dr. Chung receives funding from National Institutes of Health grant R01 HL 111314; American Heart Association COVID-19 Rapid Response Grant #814633 outside the submitted work. Mr. Milinovich reports grants from NovoNordisk, Inc, grants from Merck, Inc., grants from Novartis, and grants from Boehringer Ingelheim Pharmaceuticals, Inc, outside the submitted work. Dr. Dell reports research support from NIDDK(R01-DK114425, U01-DK110988,U01-DK066143, U54-DK083912 and NCATS (UL1T-R001445) as well as Amgen, Retrophin and Atari all outside the submitted work. Dr. Mehra reports receiving National Institutes of Health funding support from the National Heart, Lung, and Blood Institute [U01HL125177, UG3HL140144] and the American Heart Association, and has received funds for service on the American Board of Medicine Sleep Medicine Exam test writing committee, Associate Editor of the American Journal of Respiratory and Critical Care Medicine and royalties from UpToDate.

**References**
1. CDC. Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention. Published February 11, 2020. Accessed May 20, 2020. https://www.cdc.gov/coronavirus/2019-ncov/index.html

2. Wang X, Liu W, Zhao J, et al. Clinical characteristics of 80 hospitalized frontline medical workers infected with COVID-19 in Wuhan, China. *J Hosp Infect.* Published online April 14, 2020. doi:10.1016/j.jhin.2020.04.019

3. CDC COVID-19 Response Team. Characteristics of Health Care Personnel with COVID-19 - United States, February 12-April 9, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(15):477-481. doi:10.15585/mmwr.mm6915e6

4. Tostmann A, Bradley J, Bousema T, et al. Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2020;25(16). doi:10.2807/1560-7917.ES.2020.25.16.2000508

5. Li W, Zhang J, Xiao S, Sun L. Characteristics of deaths amongst health workers in China during the outbreak of COVID-19 infection. *J Infect.* Published online April 8, 2020. doi:10.1016/j.jinf.2020.03.030

6. Himmelstein DU, Woolhandler S. Health Insurance Status and Risk Factors for Poor Outcomes With COVID-19 Among U.S. Health Care Workers: A Cross-sectional Study. *Ann Intern Med.* Published online April 28, 2020. doi:10.7326/M20-1874

7. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA.* Published online February 24, 2020. doi:10.1001/jama.2020.2648

8. Bellizzi S, Fiamma M, Arru L, Farina G, Manca A. Covid-19: The daunting experience of health workers in Sardinia, Italy. *Infect Control Hosp Epidemiol.* Published online April 20, 2020:1-5. doi:10.1017/ice.2020.149

9. Heinzerling A, Stuckey MJ, Scheuer T, et al. Transmission of COVID-19 to Health Care Personnel During Exposures to a Hospitalized Patient - Solano County, California, February 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(15):472-476. doi:10.15585/mmwr.mm6915e5

10. Hunter E, Price DA, Murphy E, et al. First experience of COVID-19 screening of health-care workers in England. *Lancet Lond Engl.* Published online April 22, 2020. doi:10.1016/S0140-6736(20)30970-3

11. Chou R, Dana T, Jungbauer R, Weeks C, McDonagh MS. Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings. *Ann Intern Med.* Published online June 24, 2020. doi:10.7326/M20-3213

12. Nguyen LH, Drew DA, Joshi AD, et al. Risk of COVID-19 among frontline healthcare workers and the general community: a prospective cohort study. *MedRxiv Prepr Serv Health Sci.* Published online May 25, 2020. doi:10.1101/2020.04.29.20084111

13. Wang X, Ferro EG, Zhou G, Hashimoto D, Bhatt DL. Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. *JAMA.* Published online
July 14, 2020. doi:10.1001/jama.2020.12897

14. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 | Cell Discovery. Accessed July 10, 2020. https://www.nature.com/articles/s41421-020-0153-3

15. Milinovich A, Kattan MW. Extracting and utilizing electronic health data from Epic for research. *Ann Transl Med.* 2018;6(3):42. doi:10.21037/atm.2018.01.13

16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010

17. PubMed entry. Accessed July 10, 2020. http://www.ncbi.nlm.nih.gov/pubmed/31078660

18. Public Health Orders. Accessed July 23, 2020. https://coronavirus.ohio.gov/wps/portal/gov/covid-19/responsible-restart-ohio/Public-Health-Orders/

19. News. Florida Department of Health COVID-19 Outbreak. Accessed July 23, 2020. https://floridahealthcovid19.gov/news/

20. The State of Florida Issues COVID-19 Updates | Florida Department of Health. Accessed July 23, 2020. http://www.floridahealth.gov/newsroom/2020/05/051720-1648-covid19.pr.html

21. Li F, Thomas LE, Li F. Addressing Extreme Propensity Scores via the Overlap Weights. *Am J Epidemiol.* 2018;188(1):250-257. doi:10.1093/aje/kwy201

22. Thomas LE, Bonow RO, Pencina MJ. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol.* Published online May 5, 2020. doi:10.1001/jamacardio.2020.1874

23. Jehi L, Ji X, Milinovich A, et al. Individualizing risk prediction for positive COVID-19 testing: results from 11,672 patients. *Chest.* Published online June 10, 2020. doi:10.1016/j.chest.2020.05.580

24. Dawson P, Rabold EM, Laws RL, et al. Loss of Taste and Smell as Distinguishing Symptoms of COVID-19. *Clin Infect Dis Off Publ Infect Dis Soc Am.* Published online June 21, 2020. doi:10.1093/cid/ciaa799

25. Boscolo-Rizzo P, Borsetto D, Fabbris C, et al. Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19. *JAMA Otolaryngol– Head Neck Surg.* Published online July 2, 2020. doi:10.1001/jamaoto.2020.1379

26. Chou R, Dana T, Buckley DJ, Selph S, Fu R, Totten AM. Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers. *Ann Intern Med.* Published online May 5, 2020. doi:10.7326/M20-1632

27. Baker MA, Rhee C, Fiumara K, et al. COVID-19 infections among HCWs exposed to a patient with a delayed diagnosis of COVID-19. *Infect Control Hosp Epidemiol.* Published online undefined/ed:1-2. doi:10.1017/ice.2020.256

28. Weber DJ, Babcock H, Hayden MK, et al. Universal pandemic precautions—An idea ripe for the times. *Infect Control Hosp Epidemiol.* Published online undefined/ed:1-2. doi:10.1017/ice.2020.327
Tables

Table 1: Characteristics of All Patients Tested for SARS-CoV-2 by Health Care Worker (HCW) Status
|                                | Non-HCW Number(%) or Median[Interquartile Range] | HCW Number(%) or Median[Interquartile Range] | p-value |
|--------------------------------|--------------------------------------------------|-----------------------------------------------|---------|
| Number                         | 66764                                            | 6145                                          |         |
| SARS-CoV-2 Positive            | 4353 (6.5)                                       | 551 (9.0)                                     | <0.001  |
| **Demographics:**              |                                                  |                                               |         |
| Location                       |                                                  |                                               | <0.001  |
| Ohio                           | 50204 (75.2)                                     | 5642 (91.8)                                   |         |
| Florida                        | 13957 (20.9)                                     | 503 (8.2)                                     |         |
| Unknown                        | 2603 (3.9)                                       | 0                                             |         |
| Race                           |                                                  |                                               | <0.001  |
| Asian                          | 672 (1.0)                                        | 206 (3.4)                                     |         |
| Black                          | 12201 (18.3)                                     | 995 (16.2)                                    |         |
| Other                          | 5394 (8.1)                                       | 490 (8.0)                                     |         |
| White                          | 48497 (72.6)                                     | 4454 (72.5)                                   |         |
| Male                           | 29959 (44.9)                                     | 1322 (21.5)                                   | <0.001  |
| Non-Hispanic                   | 58496 (87.6)                                     | 5577 (90.8)                                   | <0.001  |
| Smoking                        |                                                  |                                               | <0.001  |
| Current Smoker                 | 9316 (14.0)                                      | 147 (2.4)                                     |         |
| Former Smoker                  | 30196 (45.2)                                     | 1737 (28.3)                                   |         |
| No                             | 27048 (40.5)                                     | 4259 (69.3)                                   |         |
| Unknown                        | 204 (0.3)                                        | 2 (0.0)                                       |         |
| Age                            | 57.53 [39.32, 70.26]                              | 39.67 [31.29, 51.80]                          | <0.001  |
| **Exposure history:**          |                                                  |                                               |         |
| Exposed to COVID-19            | 11369 (17.0)                                     | 4424 (72.0)                                   | <0.001  |
| Family member with COVID-19    | 9503 (14.2)                                      | 1740 (28.3)                                   | <0.001  |
| **Presenting symptoms:**       |                                                  |                                               |         |
| Cough                          | 19744 (29.6)                                     | 1968 (32.0)                                   | 0.001   |
| Fever                          | 12997 (19.5)                                     | 922 (15.0)                                    | <0.001  |
| Fatigue                        | 8020 (12.0)                                      | 637 (10.4)                                    | <0.001  |
| Sputum production              | 402 (0.6)                                        | 45 (0.7)                                      | 0.244   |
| Flu-like symptoms              | 5949 (8.9)                                       | 423 (6.9)                                     | <0.001  |
| Shortness of breath            | 17133 (25.7)                                     | 898 (14.6)                                    | <0.001  |
| Diarrhea                       | 6335 (9.5)                                       | 731 (11.9)                                    | <0.001  |
| Loss of appetite               | 1505 (2.3)                                       | 299 (4.9)                                     | <0.001  |
| Vomiting                       | 6471 (9.7)                                       | 454 (7.4)                                     | <0.001  |
| **Co-morbidities:**            |                                                  |                                               |         |
| Body Mass Index                | 28.37 [25.85, 31.07]                              | 28.37 [27.37, 29.13]                          | <0.001  |
| Chronic Obstructive Pulmonary Disease/emphysema | 8247 (12.4)                                     | 166 (2.7)                                     | <0.001  |
| Asthma                         | 12057 (18.1)                                     | 1343 (21.9)                                   | <0.001  |
| Diabetes                       | 13418 (20.1)                                     | 428 (7.0)                                     | <0.001  |
| Hypertension                   | 30727 (46.0)                                     | 1505 (24.5)                                   | <0.001  |
| Coronary artery disease        | 10181 (15.2)                                     | 204 (3.3)                                     | <0.001  |
| Heart failure                  | 8192 (12.3)                                      | 93 (1.5)                                      | <0.001  |
| Cancer                         | 12469 (18.7)                                     | 646 (10.5)                                    | <0.001  |
| Transplant history             | 1120 (1.7)                                       | 19 (0.3)                                      | <0.001  |
| Multiple sclerosis             | 493 (0.7)                                        | 43 (0.7)                                      | 0.794   |
| Connective tissue disease      | 2376 (3.6)                                       | 178 (2.9)                                     | 0.008   |
| Inflammatory Bowel Disease     | 1604 (2.4)                                       | 112 (1.8)                                     | 0.005   |
| Vaccination history:          |                |                |        |
|-------------------------------|----------------|----------------|--------|
| Influenza vaccine             | 30340 (45.4)   | 5277 (85.9)    | <0.001 |
| Pneumococcal polysaccharide  | 17808 (26.7)   | 451 (7.3)      | <0.001 |

| Laboratory findings upon presentation: |                |                |        |
|----------------------------------------|----------------|----------------|--------|
| Pre-testing platelets                  | 238.00 [238.00, 238.00] | 238.00 [238.00, 238.00] | 0.137 |
| Pre-testing AST                        | 23.00 [23.00, 23.00]  | 23.00 [23.00, 23.00]  | 0.051 |
| Pre-testing BUN                       | 16.00 [16.00, 16.00]  | 16.00 [16.00, 16.00]  | <0.001 |
| Pre-testing Chloride                  | 101.00 [101.00, 101.00] | 101.00 [101.00, 101.00] | 0.092 |
| Pre-testing Creatinine                | 0.92 [0.92, 0.92]   | 0.92 [0.92, 0.92]   | <0.001 |
| Pre-testing hematocrit                | 39.50 [39.50, 39.50] | 39.50 [39.50, 39.50] | 0.41  |
| Pre-testing Potassium                 | 4.10 [4.10, 4.10]   | 4.10 [4.10, 4.10]   | 0.081 |

| Home medications:                   |                |                |        |
|-------------------------------------|----------------|----------------|--------|
| Immunosuppressive treatment         | 2392 (3.6)     | 270 (4.4)      | <0.001 |
| Nonsteroidal Anti-inflammatory Drugs| 19651 (29.4)   | 1048 (17.1)    | <0.001 |
| Steroids                            | 11838 (17.7)   | 969 (15.8)     | <0.001 |
| Carvedilol                          | 2803 (4.2)     | 40 (0.7)       | <0.001 |
| Angiotensin converting enzyme inhibitor| 7568 (11.3) | 329 (5.4)      | <0.001 |
| Angiotensin receptor blocker        | 5698 (8.5)     | 228 (3.7)      | <0.001 |
| Melatonin                           | 3078 (4.6)     | 52 (0.8)       | <0.001 |

| Social influencers of health:       |                |                |        |
|-------------------------------------|----------------|----------------|--------|
| Population Per Square Kilometer     | 3.03 [2.63, 3.29] | 3.01 [2.64, 3.28] | 0.568 |
| Median Income per $1000             | 58.09 [41.62, 76.21] | 64.78 [49.78, 85.54] | <0.001 |
| Population Per Housing Unit         | 2.22 [1.93, 2.49] | 2.26 [2.01, 2.51] | <0.001 |

Table 2 All tested patients: Overlap Propensity Score–Weighted Characteristics a
|                     | Non-HCW | HCW  |
|---------------------|---------|------|
| Count               | 66764   | 6145 |
| Race                |         |      |
| Asian               | 2.3     | 2.3  |
| Black               | 17.9    | 17.9 |
| Other               | 8       | 8    |
| White               | 71.8    | 71.8 |
| Male                | 25.1    | 25.1 |
| Non-Hispanic        | 90.2    | 90.2 |
| Smoking             |         |      |
| Current Smoker      | 3.7     | 3.7  |
| Former Smoker       | 31.7    | 31.7 |
| No                  | 64.6    | 64.6 |
| Unknown             | 0       | 0    |
| Age                 | 43.38   | 43.38|
| Exposed to COVID-19 | 58.1    | 58.1 |
| Family member with COVID-19 | 0.1 | 0.1 |
| Cough               | 34.4    | 34.4 |
| Fever               | 18      | 18   |
| Fatigue             | 11.7    | 11.7 |
| Sputum production   | 0.9     | 0.9  |
| Flu-like symptoms   | 7.3     | 7.3  |
| Diarrhea            | 12.7    | 12.7 |
| Loss of appetite    | 4.3     | 4.3  |
| Vomiting            | 8.7     | 8.7  |
| Asthma              | 22.9    | 22.9 |
| Coronary artery disease | 4.6 | 4.6 |
| Transplant history  | 0.5     | 0.5  |
| Connective tissue disease | 3.4 | 3.4 |
| Inflammatory Bowel Disease | 2.1 | 2.1 |
| Influenza vaccine   | 79.2    | 79.2 |
| Pneumococcal polysaccharide vaccine | 11.3 | 11.3 |
| Pre-testing platelets | 240.05 | 240.05 |
| Pre-testing Aspartate Aminotransferase | 23.87 | 23.87 |
| Pre-testing Chloride | 101.05 | 101.05 |
| Pre-testing Creatinine | 0.92 | 0.92 |
| Pre-testing Hematocrit | 39.48 | 39.48 |
| Pre-testing Potassium | 4.09 | 4.09 |
| Nonsteroidal Anti-inflammatory Drugs | 20.4 | 20.4 |
| Steroids            | 17.4    | 17.4 |
| Carvedilol          | 0.9     | 0.9  |
| Angiotensin Converting Enzyme inhibitor | 6.7 | 6.7 |
| Angiotensin Receptor Blocker | 4.9 | 4.9 |
| Melatonin           | 1.2     | 1.2  |
| Population Per Square Kilometer | 2.92 | 2.92 |
| Median Income (thousands of dollars) | 68.20 | 68.20 |
|                              | Value 1 | Value 2 |
|------------------------------|---------|---------|
| Body Mass Index              | 2.92    | 2.92    |
| Final Result = Positive Test for SARS-CoV-2 | 7.7     | 8.9     |
| Odds Ratio (95% Confidence Interval) | 1.17 (0.99, 1.38) | 1.17 (0.99, 1.38) |

a Reported are either weighted proportions (for categorical variables) or weighted means (for numeric variables)

Table 3 All test positive patients: Overlap Propensity Score–Weighted Characteristics a
|                      | Non-HCW | HCW |
|----------------------|---------|-----|
| **Count**            | 4353    | 551 |
| **Race**             |         |     |
| Asian                | 2.1     | 2.1 |
| Black                | 28.6    | 28.6|
| Other                | 9.4     | 9.4 |
| White                | 59.9    | 59.9|
| **Male**             | 30.7    | 30.7|
| **Ethnicity**        |         |     |
| Hispanic             | 3.3     | 3.3 |
| Non-Hispanic         | 90.2    | 90.2|
| Unknown              | 6.4     | 6.4 |
| **Smoking**          |         |     |
| Current Smoker       | 2.9     | 2.9 |
| Former Smoker        | 18.6    | 18.6|
| No                   | 73.7    | 73.7|
| Unknown              | 4.8     | 4.8 |
| **Age**              | 43.50   | 43.50|
| **Fever**            | 44.8    | 44.8|
| Fatigue              | 55.2    | 55.2|
| Shortness of breath  | 37      | 37  |
| Diarrhea             | 35      | 35  |
| Vomiting             | 24.7    | 24.7|
| Asthma               | 12.6    | 12.6|
| Diabetes             | 10.4    | 10.4|
| Hypertension         | 22.2    | 22.2|
| Immunosuppressive treatment | 6.9 | 6.9 |
| Immunosuppressive disease | 4.5 | 4.5 |
| Pre-testing platelets| 234.70  | 234.70|
| Pre-testing Aspartate Aminotransferase | 24.51 | 24.51|
| Pre-testing Blood Urea Nitrogen | 15.76 | 15.76|
| Pre-testing Chloride | 100.04  | 100.04|
| Pre-testing Potassium| 3.99    | 3.99|
| Nonsteroidal Anti-inflammatory Drugs | 17.4 | 17.4|
| Median Income (thousands of dollars) | 62.25 | 62.25|
| Population Per Housing Unit | 2.22 | 2.22|
| Body Mass Index      | 29.63   | 29.63|
| **Final Result = Hospitalization** | 15.9 | 7.4 |
| **Odds Ratio (95% Confidence Interval)** | 0.42 (0.26, 0.66) | 0.48 (0.20, 1.04) |

*Reported are either weighted proportions (for categorical variables) or weighted means (for numeric variables)*
Figures

Figure 1

(Top): Odds of SARS-CoV-2 positive test, Hospital Admission if SARS-CoV-2 positive, and Intensive Care Admission if SARS-CoV-2 positive by Healthcare Worker (HCW) Status

(Bottom): Odds of SARS-CoV-2 positive test, Hospital Admission if SARS-CoV-2 positive, and Intensive Care Admission if SARS-CoV-2 positive by Patient-Facing and Non-Patient Facing Healthcare Worker Status

OR = odds ratio, LCL = Lower Confidence Limit, UCL = Upper Confidence Limit
Figure 2

Proportion of SARS-CoV-2 Positive Results During Study Period

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- MisraHebertHCWAppendices07232020.docx